Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead
Open accessThe DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
The Journal of Cancer Metastasis and Treatment is an open access journal focused on cancer metastasis and treatment, including the occurrence, development, progression, metastasis, and treatment of oncologic disease. It covers basic, translational and clinical research related to cancer cell biology, genomics, precision medicine, oncology internal medicine, radiotherapy and radiology, obstetrics and gynecology, pediatrics, surgery, hematology, neurooncology, etc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116 · cited 1×
“255 short) technique is a much simpler and more efficient method of editing genes than previous methods, and was first reported in 2012[49].”
MethodMultiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
A human homologue of the Drosophila Toll protein signals activation of adaptive immunity
Medzhitov, R., Preston-Hurlburt, P., & Janeway, C. A. (1997) · Nature · doi:10.1038/41131 · Cited by 5,590
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“The intrinsic immunological ability of an individual to combat cancer has been called the “cancer– immune set point”, and is influenced by a complex set of factors involving the tumor, the host, and environmental factors[41].”
Background
Cited by
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Schirrmacher, V. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4661 · Cited by 1,296
Cancer and the Immune System: The History and Background of Immunotherapy
Abbott, M., & Ustoyev, Y. (2019) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2019.08.002 · Cited by 489
The Intriguing History of Cancer Immunotherapy
Dobosz, P., & Dzieciątkowski, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02965 · Cited by 458
Emerging therapeutic agents for advanced non-small cell lung cancer
Chen, R., Manochakian, R., James, L., Azzouqa, A.-G., Shi, H., Zhang, Y., Zhao, Y., Zhou, K., & Lou, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00881-7 · Cited by 340
Zhang, M., Liu, C., Tu, J., Tang, M., Ashrafizadeh, M., Nabavi, N., Sethi, G., Zhao, P., & Liu, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02305-x · Cited by 259
Cell membrane coated-nanoparticles for cancer immunotherapy
Zeng, Y., Li, S., Zhang, S., Wang, L., Yuan, H., & Hu, F. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.023 · Cited by 238
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Arafat Hossain, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 178
Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer
Sharma, M., Bakshi, A. K., Mittapelly, N., Gautam, S., Marwaha, D., Rai, N., Singh, N., Tiwari, P., Agarwal, N., Kumar, A., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.007 · Cited by 84
Dhiman, V., & Pant, D. (2021) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2020.1844751 · Cited by 41
The impact of AI on modern oncology from early detection to personalized cancer treatment
Li, J., Zhang, L., Yu, Z., Bao, Z., Li, D., & Wang, L. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01276-6 · Cited by 24
Recent developments in antibody derivatives against colorectal cancer; A review
Ghani, S., Bahrami, S., Rafiee, B., Eyvazi, S., Yarian, F., Ahangarzadeh, S., Khalili, S., Shahzamani, K., Jafarisani, M., Bandehpour, M., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118791 · Cited by 20
An in-depth review of AI-powered advancements in cancer drug discovery
Le, M. H. N., Nguyen, P. K., Nguyen, T. P. T., Nguyen, H. Q., Tam, D. N. H., Huynh, H. H., Huynh, P. K., & Le, N. Q. K. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167680 · Cited by 15
Metadata
- Authors
- Oiseth, S. J., & Aziz, M. S.
- Venue
- Journal of Cancer Metastasis and Treatment
- Publisher
- OAE Publishing Inc.
- Published
- 2017-10-31
- Volume
- 3
- Issue
- 10
- Pages
- 250
- ISSN
- 2394-4722 (ISSN-L)
- 2454-2857
- OpenAlex
- W2765238085
- Cited by
- 369
- References
- 98
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.